New hope for Tough-to-Treat cancer: drug trial aims to extend lives

NCT ID NCT01843374

Ongoing Disease control Sponsor: MedImmune LLC Source: ClinicalTrials.gov ↗

Summary

This study is testing whether an immunotherapy drug called tremelimumab can help people with advanced mesothelioma live longer when standard treatments have stopped working. About 571 patients whose cancer cannot be removed by surgery will receive either tremelimumab or a placebo. The main goal is to see if the drug improves overall survival compared to the placebo.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE PLEURAL OR PERITONEAL MALIGNANT MESOTHELIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Scottsdale, Arizona, 85259, United States
Research Site

La Jolla, California, 92093, United States
Research Site

Los Angeles, California, 90025, United States
Research Site

San Francisco, California, 94143, United States
Research Site

Santa Monica, California, 90404, United States
Research Site

New Haven, Connecticut, 06511, United States
Research Site

Newark, Delaware, 19718, United States
Research Site

Tampa, Florida, 33612, United States
Research Site

Augusta, Georgia, 30912, United States
Research Site

Chicago, Illinois, 60637, United States
Research Site

Peoria, Illinois, 61615, United States
Research Site

Baltimore, Maryland, 21201, United States
Research Site

Baltimore, Maryland, 21231, United States
Research Site

Minneapolis, Minnesota, 55445, United States
Research Site

New York, New York, 10065, United States
Research Site

Rochester, New York, 14642, United States
Research Site

Durham, North Carolina, 27710, United States
Research Site

Canton, Ohio, 44710, United States
Research Site

Philadelphia, Pennsylvania, 19104, United States
Research Site

Dallas, Texas, 75390, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Adelaide, 5000, Australia
Research Site

Auchenflower, 4066, Australia
Research Site

Box Hill, 3128, Australia
Research Site

Chermside, 4032, Australia
Research Site

East Bentleigh, 3165, Australia
Research Site

Gosford, 2250, Australia
Research Site

Heidelberg, 3084, Australia
Research Site

Nedlands, 6009, Australia
Research Site

Saint Leonards, 2065, Australia
Research Site

Waratah, 2298, Australia
Research Site

Edegem, 2650, Belgium
Research Site

Ghent, 9000, Belgium
Research Site

Leuven, 3000, Belgium
Research Site

Toronto, Ontario, M5G 2M9, Canada
Research Site

Sainte-Foy, Quebec, G1V 4G5, Canada
Research Site

Copenhagen, 2100, Denmark
Research Site

Caen, 14076, France
Research Site

Le Mans, 72037, France
Research Site

Lille, 59037, France
Research Site

Nice, 06189, France
Research Site

Rennes, 35033, France
Research Site

Toulouse, 31059, France
Research Site

Villejuif, 94805, France
Research Site

Berlin, 13125, Germany
Research Site

Esslingen a.N., 73730, Germany
Research Site

Freiburg im Breisgau, 79106, Germany
Research Site

Gauting, 82131, Germany
Research Site

Großhansdorf, 22927, Germany
Research Site

Hamburg, 21075, Germany
Research Site

Hemer, 58675, Germany
Research Site

Karlsruhe, 76137, Germany
Research Site

Löwenstein, 74245, Germany
Research Site

Lübeck, 23538, Germany
Research Site

Gyöngyös - Mátraháza, 3200, Hungary
Research Site

Törökbálint, 2045, Hungary
Research Site

Beersheba, 84101, Israel
Research Site

Alessandria, 15100, Italy
Research Site

Aviano, 33081, Italy
Research Site

Bergamo, 24125, Italy
Research Site

Bologna, 40138, Italy
Research Site

Candiolo, 10060, Italy
Research Site

Genova, 16132, Italy
Research Site

Meldola, 47014, Italy
Research Site

Milan, 20133, Italy
Research Site

Orbassano, 10043, Italy
Research Site

Padua, 35128, Italy
Research Site

Rozzano, 20089, Italy
Research Site

Siena, 53100, Italy
Research Site

Breda, 4818 CK, Netherlands
Research Site

Eindhoven, 5623EJ, Netherlands
Research Site

Rotterdam, 3015 GD, Netherlands
Research Site

Gdansk, 80-952, Poland
Research Site

Poznan, 60-693, Poland
Research Site

Szczecin, 70-891, Poland
Research Site

Warsaw, 02-781, Poland
Research Site

Craiova, 200385, Romania
Research Site

Moscow, 115478, Russia
Research Site

Nizhny Novgorod, 603006, Russia
Research Site

Saint Petersburg, 197022, Russia
Research Site

Kraaifontein, 7570, South Africa
Research Site

Pretoria, 0081, South Africa
Research Site

Pretoria, 0181, South Africa
Research Site

Jeonnam, 58128, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Barcelona, 08035, Spain
Research Site

Donostia / San Sebastian, 20014, Spain
Research Site

Madrid, 28040, Spain
Research Site

Sabadell (Barcelona), 08208, Spain
Research Site

Seville, 41013, Spain
Research Site

Linköping, 58185, Sweden
Research Site

Lund, 22185, Sweden
Research Site

Umeå, SE90185, Sweden
Research Site

Leeds, LS9 7TF, United Kingdom
Research Site

Leicester, LE1 5WW, United Kingdom
Research Site

London, EC1A 7BE, United Kingdom
Research Site

London, SE1 9RT, United Kingdom
Research Site

Maidstone, ME16 9QQ, United Kingdom
Research Site

Manchester, M23 9LT, United Kingdom
Research Site

Metropolitan Borough of Wirral, CH63 4JY, United Kingdom
Research Site

Plymouth, PL6 8DH, United Kingdom
Research Site

Southampton, SO16 6YD, United Kingdom

Conditions

Explore the condition pages connected to this study.

UNRESECTABLE PLEURAL OR PERITONEAL MALIGNANT MESOTHELIOMA